Unibest

Pharmaceutical intermediates

Contezolid Intermediates

2 pharmaceutical intermediates for Contezolid. Indication: Complicated Skin and Skin Structure Infections.

Submit a ProjectAll intermediates

About Contezolid

Originator
MicuRx
Indication
Complicated Skin and Skin Structure Infections
Approved Date
10/02/2018
NCE Patent
10/02/2028
DS/DP
06/02/2025

Available intermediates

2 intermediates currently listed for Contezolid. Request specifications, documentation or a quotation for any item below.

Contezolid intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1112968-95-21112968-95-2//
Carbamic acid, 3-isoxazolyl-, 1,1-dimethylethyl ester (9CI)264600-97-7//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Capmatinib Hydrochloride

Building toward Contezolid?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →